• Pharmaceutical M&As: Tracking the trends

• New crop of nucleic-acid-based drugs on the horizon

• Deals stack up around migraine’s new target

• Platform biotechs harvest the fruits of independence

• Immuno-oncology: the rise of the checkpoint inhibitors

• Next-generation antibodies land string of deals

• Emerging viral epidemics catalyze vaccine dealmaking

• How do you value a pharmaceutical deal?

• Biopharma and academia explore new partnership models

• Inflammation in numbers

• Advanced sequencing technologies facilitate precision medicine

• Dealing in diagnostics

• Drug delivery: Hunting for innovative technologies

• Can digital health reshape disease management?

No stone unturned in the search for winning immuno-oncology combination therapies